{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:15Z","timestamp":1794047475124,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"12","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2024.285278","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T04:45:25Z","timestamp":1721277925000},"page":"4100-4105","source":"Crossref","is-referenced-by-count":2,"title":["Minimal residual disease assessment in transplant-eligible patients with multiple myeloma: real-world applications of multiparametric flow cytometry-DURAClone (CAREMM-2104)"],"prefix":"10.3324","volume":"109","author":[{"given":"Ari","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Mi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myungshin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"70231","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016; 101(4):396-406.","DOI":"10.3324\/haematol.2015.129189"},{"key":"70232","doi-asserted-by":"crossref","unstructured":"Paiva B, Guti\u00e9rrez NC, Rosi\u00f1ol L. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012; 119(3):687-691.","DOI":"10.1182\/blood-2011-07-370460"},{"key":"70233","doi-asserted-by":"crossref","unstructured":"Yim J, Park SS, Lee JM, Yoon JH, Kim HJ, Min CK. Successful recovery of poor graft function by administration of romiplostim in a multiple myeloma case with poor graft function following autologous stem cell transplantation. Blood Res. 2023; 58(4):237-240.","DOI":"10.5045\/br.2023.2023185"},{"key":"70234","doi-asserted-by":"crossref","unstructured":"Stetler\u2010Stevenson M, Paiva B, Stoolman L. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry B Clin Cytom. 2016; 90(1):26-30.","DOI":"10.1002\/cyto.b.21249"},{"key":"70235","doi-asserted-by":"crossref","unstructured":"Byun JM, Park SS, Yoon SS. Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study. Blood Res. 2023; 58(2):83-90.","DOI":"10.5045\/br.2023.2023005"},{"key":"70236","doi-asserted-by":"crossref","unstructured":"Arroz M, Came N, Lin P. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016; 90(1):31-39.","DOI":"10.1002\/cyto.b.21228"},{"key":"70237","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"70238","doi-asserted-by":"crossref","unstructured":"Kim SI, Jung SH, Yhim HY. Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen. Blood Res. 2022; 57(1):51-58.","DOI":"10.5045\/br.2021.2021176"},{"key":"70239","doi-asserted-by":"crossref","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022; 97(8):1086-1107.","DOI":"10.1002\/ajh.26590"},{"key":"70240","doi-asserted-by":"crossref","unstructured":"Cho Y-U. The role of next-generation sequencing in hematologic malignancies. Blood Res. 2024; 59(1):11.","DOI":"10.1007\/s44313-024-00010-0"},{"key":"70241","doi-asserted-by":"crossref","unstructured":"Yoroidaka T, Narita K, Takamatsu H, Fujisawa M, Nakao S, Matsue K. Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods. Sci Rep. 2021; 11(1):11218.","DOI":"10.1038\/s41598-021-89761-9"},{"key":"70242","doi-asserted-by":"crossref","unstructured":"Blum A, Haussmann K, Streitz M. Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma. Sci Rep. 2019; 9(1):2922.","DOI":"10.1038\/s41598-019-39631-2"},{"key":"70243","doi-asserted-by":"crossref","unstructured":"Martinez-Lopez J, Lahuerta JJ, Pepin F. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014; 123(20):3073-3079.","DOI":"10.1182\/blood-2014-01-550020"},{"key":"70244","doi-asserted-by":"crossref","unstructured":"San-Miguel J, Avet-Loiseau H, Paiva B. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022; 139(4):492-501.","DOI":"10.1182\/blood.2020010439"},{"key":"70245","doi-asserted-by":"crossref","unstructured":"de Tute RM, Pawlyn C, Cairns DA. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J Clin Oncol. 2022; 40(25):2889-2900.","DOI":"10.1200\/JCO.21.02228"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285278\/77288","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285278\/77847","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11695\/77288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:55Z","timestamp":1794046015000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":15,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285278","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,18]]}}}